First treatment for common bladder cancer recommended by NICE
Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration
Read More
Tag: Urothelial cancer
Hundreds of urothelial cancer patients to receive new treatment
NICE recommends avelumab as treatment for adults with locally advanced or metastatic urothelial cancer
Read More
Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read More
Final NICE no for BMS’ Opdivo in urothelial carcinoma
The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
Read More
NICE rejects Roche’s Tecentriq for pre-treated urothelial cancer
Cost regulators for NHS treatments in England and Wales have turned down Roche’s Tecentriq for patients who have already received prior treatment for metastatic urothelial cancer.
Read More
NICE back Roche’s Tecentriq for CDF
The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.
Read More
NICE no for Opdivo in urothelial carcinoma
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
Read More
NICE leans towards a ‘no’ for Keytruda in urothelial cancer
Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as a treatment for locally advanced or metastatic urothelial cancer.
Read More
Priority review for Merck, Pfizer’s avelumab in urothelial cancer
US regulators have agreed to undertake a priority review Merck and Pfizer’s avelumab as a potential treatment for metastatic urothelial carcinoma (mUC).
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
